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treatment thereafter, their prognosis has been improving. We 
analyzed the results of our 18-year experience. 
Materials and Methods: Between 1993 and April 2011 48 
patients (68 times) were treated. Their age ranged from 46 
to 86 with a median of 64. There were 20 male patients and 
28 females. Seventeen patients were unable to walk before 
IORT, while the remaining 31 were ambulant. IORT was given 
with proper energy electron beam from posteriorly shielding 
the spinal cord with lead of proper thickness. The doses of 
IORT ranged from 16Gy to 26Gy with a median of 20Gy. Ten 
patients received IORT more than once (2 to 6 times). 
External beam radiation therapy was administered in 29 
patients, of which 1 received preoperatively (24Gy), 20 
received postoperatively (20~40Gy, median 35.5Gy). All 
patients received thyroid stimulating hormone suppression 
therapy. Radioactive iodines (Iodine-131) were administered 
in 29 patients. Median follow-up period was 33 months. 
Results: Among 17 patients who had been unable to walk 15 
became able to walk following IORT, while the remaining 2 
died soon after the treatment (response: not evaluable). 
Overall median survival time of overall patients was 38 
months. Three- and 5-year overall survival rates were 51% 
and 33%, respectively. Symptomatic recurrence was observed 
in 6 cases (14%).  
Conclusions: Well-differentiated thyroid cancer patients 
carried quite favorable prognoses considering their status 
prior to IORT. From our experience, aggressive treatment was 
justified since more than half of the patients survived 3 years 
and about one third of the patients survived 5 years. 
Furthermore, only small portion of the patients suffered from 
symptomatic recurrence. Our methods were very promising 
both for quantity and quality of life in the treatment of 
spinal metastases from well-differentiated thyroid cancer. 
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Purpose/Objective: Kyphoplasty combined with 
intraoperative radiotherapy (Kypho-IORT) is a novel 
treatment modality for patients with spinal metastases. The 
technical feasibility and the operation principle of this 
approach have been described. In this study we present the 
results of the conducted phase II dose escalation study (NCT 
01280032) and update the clinical data of a pilot phase. 
Materials and Methods: For Kypho-IORT the INTRABEAM 
system (Carl Zeiss Surgical, Oberkochen, Germany) with a 
specially designed applicator was used. In the phase II study 
three dose escalation levels were tested: 8 Gy in 8 mm, 8 Gy 
in 10mm and 8 Gy in 13 mm depth from the isocenter of the 
radiation source. Inclusion criteria were age of ≥ 50 years, 
Karnofsky-Index of ≥ 60% and histologically or radiologically 
documented spinal metastases (≤ 2cm) caudal the 3rd thoracic 
vertebra. Off-study patients were treated analogue the first 
two dose levels. 
Results: Overall 61 patients received a Kypho-IORT. 9 
patients were included in the phase II dose escalation study, 
the remaining 52 patients were treated off-study in a pilot 
phase. For the whole cohort the 3, 6 and 12 months overall 
survival was 76.9%, 64.0% and 48.4%. The 3, 6 and 12 months 
local progression free survival was 97.5%, 93.8% and 93.8%. 
There was a significantly pain reduction from median VAS 
5/10 before Kypho-IORT to median VAS 2/10 first day after 
Kypho-IORT (p<0.001). 3, 6 and 9 months after Kypho-IORT 
also a significantly pain reduction compared to the 
preoperative situation was seen in the entire cohort (n= 33, 
21, 18 patients, respectively; all p <0.005). For the on-study 
patients the 3, 6 and 12 months local PFS was 100%, 83.3% 
and 83.3%. The median pain improvement was also significant 
(VAS 4/10 preoperatively vs. VAS 1/10 postoperatively, 
p=0.018). For the off-study patients the 3, 6 and 12 months 
local PFS was 96.9% respectively. The median pain score 
significantly improved from VAS 5/10 before the procedure to 
VAS 2/10 at the first postoperative day (p<0.001). There 
were no dose-limiting toxicities in the three dose escalation 
levels. 
Conclusions: Kypho-IORT is an alternative therapy approach 
for patients with spinal metastases in the palliative 
treatment setting with good local tumor control and 
immediate and permanent pain relief without severe side 
effects. A dose of 8 Gy in 13 mm depths from the isocenter 
could be determined as a save maximally tolerated dose and 
will be consolidated in a phase III study.  
   
OC-0521   
IORT after gross total resection combined with EBRT in 
extremity soft tissue sarcoma: a pooled analysis  
F. Roeder1, A. De Paoli2, I. Alldinger3, G. Bertola2, G. Boz2, 
J.L. Garcia-Sabredo4, M. Uhl5, A. Alvarez6, B. Lehner7, F.A. 
Calvo6, R. Krempien8 
1University of Munich (LMU), Radiation Oncology, München, 
Germany  
2National Cancer Institute CRO, Radiation Oncology, Aviano, 
Italy  
3University of Heidelberg, Surgery, Heidelberg, Germany  
4University Hospital Gregorio Maranon, Surgery, Madrid, 
Spain  
5University of Heidelberg, Radiation Oncology, Heidelberg, 
Germany  
6University Hospital Gregorio Maranon, Radiation Oncology, 
Madrid, Spain 
7University of Heidelberg, Orthopedics, Heidelberg, Germany  
8Helios Clinic, Radiation Oncology, Berlin-Buch, Germany  
 
Purpose/Objective: In 2009 we reported promising first 
results of a European pooled analysis which evaluated the use 
of intraoperative radiation therapy (IORT) in the treatment of 
soft tissue sarcomas. However, comparison of these results 
with non-IORT series seemed difficult, mainly because of the 
inclusion of grossly incomplete resected lesions, patients 
treated without additional external beam radiation therapy 
(EBRT) and comparatively short follow-up. Therefore we 
aimed to re-analyze our data limited to the patients who 
received IORT preceeded or followed by EBRT after gross 
total resection with extended follow-up.  
Materials and Methods: Three European expert centers 
participated in the current analysis. Patients with gross 
incomplete resection, missing documentation of EBRT or 
lesions outside the extremities were excluded, leaving 250 
patients for analysis. Individual patient and treatment 
characteristics including gender, age, disease situation, 
timing and dose of EBRT component, surgical procedure, 
resection margin, use of chemotherapy and IORT 
specifications as well as the onset of oncological events like 
local/distant recurrence or death and treatment related 
effects like severe toxicities and complications were fully re-
analyzed according to the patient's treatment and follow-up 
charts.  
Results: Overall results including Kaplan-Meier estimates for 
local control, distant control and overall survival will be 
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presented for the entire cohort. Univariate and multivariate 
subgroup analysis will be performed to identify possible 
prognostic factors using the log rank test and the Cox 
regression method, respectively. Rates of severe side effects 
and complication rates will be reported descriptively.  
Conclusions: This pooled analysis offers the opportunity to 
evaluate the efficacy and toxicity of a multimodal treatment 
approach including IORT, EBRT and gross total limb-sparing 
surgery in a large series of patients with extremity sarcoma 
treated in European expert centers and therefore may serve 
as a benchmark for other treatment approaches.  
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Purpose/Objective: Patients with locally advanced rectal 
cancer have a dismal prognosis. 
Materials and Methods: We investigated outcomes in 77 
consecutive patients with T4 tumors treated with 
preoperative chemoradiotherapy (CRT), surgery and IOERT. 
Results: Median follow-up was 62.8 months (range, 4-198). 5 
year Loco-regional control, disease-free survival and overall 
survival was 84%, 68% and 65%. 
Conclusions: Overall results after multimodality treatment of 
T4 are promising. Classification of risk factors for LRR would 
contributed to propose a prognostic index that could allow us 
to guide risk-adapted tailored treatment  
 
 
Poster Discussion: Dose modelling and planning  
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Purpose/Objective: In radiotherapy treatment planning for 
patients with tumor relapse, a number of factors must be 
taken into account, such as prior treatments to the area, 
total dose to critical organs, and dose-per-fraction effects 
within the patient volume. The aim of this study was to 
develop a simple tool to explore 3D biological dose 
summation with non-rigid fusion, and to demonstrate its 
importance in treatment planning. 
Materials and Methods: Fine-scale deformable image 
registration was carried out in Mirada RTx™ (Mirada Medical 
Ltd., Oxford, UK), and inspected for plausibility using 
registration QC tools (see Fig 1C). The deformation grids 
were used to transform dose distributions from prior 
treatments into the space of the current target CT. Thus, 
given the number of fractions in each treatment plan, the 
fractional doses for every voxel in the new planning CT 
volume were calculated for each treatment. 
The software used the linear-quadratic (LQ) model for 
equivalence calculations, and doses were expressed as 2Gy 
equivalent dose (EQD2), which were summed voxel-wise to 
give the EQD2 for the total treatment. The interface was 
designed to allow users to specify different alpha/beta-ratios 
per structure on the planning CT, and also to enter a healing 
parameter to down-scale effects of past treatments. 
An illustrative H&N case is presented. A malignancy on the 
left side of the tongue received standard three dose level 
simultaneously integrated boost (SIB) treatment 
(33x2/1.82/1.64Gy at 66/60/54Gy) with a seven field 6MV 
IMRT technique. The planning CT and PTVs are shown in Fig 
1A. Two years after the primary treatment, the patient 
experienced a relapse on the right side, and a 25x2Gy 
treatment was planned for the new PTV (Fig 1B). Even after 
positioning the patient to minimize the difference between 
CTs, the large tissue deformations due to tumor mass and 
neck rigidity presented a challenging registration problem. 
Total doses (in EQD2) to critical organs were investigated, 
using alpha/beta-ratios of 2.1Gy for the medulla, and 3Gy for 
other organs.  
 
 
 
